WO2024256731 - A CHOLECYSTOKININ (CCK) ANTAGONIST FOR USE IN THE PREVENTION AND/OR TREATMENT OF A VESTIBULAR DISEASE OR DISORDER
National phase entry is expected:
Publication Number
WO/2024/256731
Publication Date
19.12.2024
International Application No.
PCT/EP2024/072753
International Filing Date
12.08.2024
Title **
[English]
A CHOLECYSTOKININ (CCK) ANTAGONIST FOR USE IN THE PREVENTION AND/OR TREATMENT OF A VESTIBULAR DISEASE OR DISORDER
[French]
ANTAGONISTE DE CHOLÉCYSTOKININE (CCK) DESTINÉ À ÊTRE UTILISÉ DANS LA PRÉVENTION ET/OU LE TRAITEMENT D'UNE MALADIE OU D'UN TROUBLE VESTIBULAIRE
Applicants **
UNIVERSITAT AUTONOMA DE BARCELONA
Inventors
QUINTANA ROMERO, Albert
SÁNCHEZ BENITO, Laura
MACHUCA MÁRQUEZ, Pablo
SANZ IGLESIAS, Elisenda
Priority Data
23382592.6
15.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2363 | |
| EPO | Filing, Examination, Granting | 11667 | |
| Japan | Filing, Examination, Granting | 2400 | |
| South Korea | Filing, Examination, Granting | 2558 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
24,928
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a cholecystokinin (CCK) antagonist for use in the prevention and/or treatment of a vestibular disease or disorder selected from motion sickness, Meniere's disease, vestibular migraine, disembarkment sickness, labyrinthitis, vestibular neuronitis, benign paroxysmal positional vertigo, and labyrinthine infarction. It also relates to a drug combination comprising a CCK antagonist and a GLP1 receptor agonist, to compositions comprising this combination, and to a CCK antagonist for use in the treatment and/or prevention of adverse side effects associated to a GLP1 receptor agonist, in a subject undergoing therapy with a GLP1 receptor agonist.[French]
La présente invention concerne un antagoniste de cholécystokinine (CCK) destiné à être utilisé dans la prévention et/ou le traitement d'une maladie ou d'un trouble vestibulaire choisi parmi le mal des transports, la maladie de Ménière, la migraine vestibulaire, le mal de débarquement, la labyrinthite, la névrite vestibulaire, le vertige paroxystique positionnel bénin, et l'infarctus labyrinthique. L'invention concerne également une combinaison de médicaments comprenant un antagoniste de CCK et un agoniste du récepteur GLP1, des compositions comprenant cette combinaison, et un antagoniste de CCK destiné à être utilisé dans le traitement et/ou la prévention d'effets secondaires indésirables associés à un agoniste du récepteur GLP1, chez un sujet subissant une thérapie avec un agoniste du récepteur GLP1.